TAILOR RT: A Randomized trial of regional radiotherapy in biomarker low risk node positive and T3N0 breast cancer.
(CompassHER2-pCR)-Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials.
Optimizing Endocrine Therapy Through Motivational Interviewing And Text Interventions.
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer.
This registry assesses patients undergoing initial (primary) endovascular repair of an AAA where the investigator believes the proximal aortic neck is challenging such that the risk of failure or fixation and/or sealing is great enough that the use of the Heli-FX EndoAnchor System is warranted.
This prospective clinical trial compares drug eluding stents to drug coated stents in peripheral vascular diseases of the lower extremity.
This endovascular treatment for the thoracic aorta provides a less invasive option for diseases of the descending thoracic aorta. This treament is available for aneurysms and all Type B dissections.
Intermacs is a North American registry for the clinical outcomes of patients who receive an FDA-approved mechanical circulatory support device to treat advanced heart failure.
This registry is a collaboration between the Society for Thoracic Surgeons and the ACC and monitors patient safety and real-world outcomes related to transcatheter valve replacement and repair procedures – emerging treatments for valve disease patients. Employing state-of-the-art heart valve technology, transcatheter heart valve procedures provide new treatment options for…
This is the first national registry capturing data on left atrial appendage occlusion procedures to assess real-world procedural outcomes, short and long-term safety, comparative effectiveness, and cost-effectiveness.